Collectively, functional perturbations of PYCR1 revealed a role for this metabolic protein in tumor progression and response to treatment and support the observations from our clinical proteomics data, wherein residual tumors with high PYCR1 level are associated with resistance to treatment and with poor clinical outcome. This evidence concerns the gene PYCR1 and neoplasm.